Briacell Therapeutics Corp. Debt Actions Announcement


BERKELEY, Calif. And VANCOUVER, British Columbia, August 11, 2020 (GLOBE NEWSWIRE) – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V: BCT) (OTCQB: BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces it has entered into a debt settlement agreement (“Debt settlement“) with a creditor, who has provided legal services to the Company, to settle, or partially settle, some of the Company’s unpaid debts owed to them in exchange for the issuance of ordinary shares (“Actions“) of the Company. It is proposed to issue a total of 50,000 shares at a deemed price of C $ 7.48 per share to settle the debt of C $ 374,000 owed to creditors under this debt settlement. .

Completion of the debt settlement is subject to the approval of the TSX Venture Exchange. All securities issued under the Debt Settlement will be subject to a hold period of four months and one day from the date of issue, in accordance with applicable securities laws.

About BriaCell

BriaCell is an immuno-oncology-focused biotechnology company that develops targeted and effective approaches for cancer management.

For more information on BriaCell, please visit:

Caution regarding forward-looking information

Except for statements of historical fact, this press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation (also referred to as “forward-looking statements”) that is subject to known and unknown risks relevant to the society. in particular and for the biotechnology and pharmaceutical industries in general, uncertainties and other factors which may cause actual events to differ materially from current expectations. These risks are described in more detail in the Company’s public documents available at

These forward-looking statements include, without limitation, BriaCell’s plans, objectives, expectations and intentions. These forward-looking statements reflect BriaCell’s current beliefs and are based on information currently available to management. Although the forward-looking statements contained in this press release are based on what BriaCell considers to be reasonable assumptions, there can be no assurance that actual results will be consistent with these forward-looking statements.

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise forward-looking statements, whether as a result of new information, future events or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact details

For more information, please contact:

BriaCell Therapeutics Corp. :
William V. Williams, MD
President and CEO
Phone: 1-888-485-6340

BriaCell Therapeutics Corp. :
Farrah Dean
Manager, Corporate Development
E-mail: [email protected]
Phone: 1-888-485-6340


Comments are closed.